AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18809272 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Subtraction Angiography (DSA)
Number of subjects: 51
Study 18809272 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D time‐of‐flight MR angiography (TOF‐MRA) at 3 Tesla (3T)
Number of subjects: 51
Study 17932102 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1522
Study 17932102 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic therapy (FT)
Number of subjects: 1522
Study 17932102 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI group overall
Number of subjects: 1522
Study 17932102 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI group with anterior EMI without ECG signs of reperfusion
Number of subjects: 1522
Study 15129929 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (CHO)
Number of subjects: 8
Study 15129929 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (FAT)
Number of subjects: 8
Study 15129929 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet combined with training (FAT+T)
Number of subjects: 8
Study 15129929 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet combined with training (CHO+T)
Number of subjects: 8
Study 15129929 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CHO+T and FAT+T)
Number of subjects: 8
Study 11826486 — intervention group
Group type: EXPERIMENTAL
Intervention: Aranoza
Number of subjects: 0
Study 9214140 — intervention group
Group type: EXPERIMENTAL
Intervention: Various carbohydrate-containing products
Number of subjects: 0
Study 9214140 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Russian food and dishes
Number of subjects: 0
Study 8225637 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (125 mg for <25 kg or 250 mg for >25 kg, twice daily for 5 days)
Number of subjects: 259
Study 8225637 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (125 mg for <25 kg or 250 mg for >25 kg, three times daily for 5 days)
Number of subjects: 259
Study 2871241 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 1162
Study 2871241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study 31584149 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-Based Chaplaincy Intervention
Number of subjects: 23
Study 31584149 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control Condition
Number of subjects: 23
Study 30579352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial portal method
Number of subjects: 104
Study 30579352 — intervention group
Group type: COMPARATOR
Intervention: Transtibial method
Number of subjects: 104
Study 30579352 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 27178892 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids nasal strips
Number of subjects: 40
Study 27178892 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nasal strips
Number of subjects: 40
Study 24321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 95
Study 24321619 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroid injection
Number of subjects: 95
Study 22957034 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages (n = 600)
Number of subjects: 1200
Study 22957034 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 600)
Number of subjects: 1200
Study 22957034 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messages
Number of subjects: 1200
Study 22957034 — intervention group
Group type: EXPERIMENTAL
Intervention: Men paying > US$1.25 for travel
Number of subjects: 1200
Study 22957034 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with secondary or higher education
Number of subjects: 1200
Study 20140447 — intervention group
Group type: EXPERIMENTAL
Intervention: SDEP (Sleep Deprivation)
Number of subjects: 10
Study 20140447 — intervention group
Group type: EXPERIMENTAL
Intervention: SDEP + ER (Sleep Deprivation + Energy Restriction)
Number of subjects: 10
Study 20140447 — intervention group
Group type: COMPARATOR
Intervention: CON (Control)
Number of subjects: 10
Study 20140447 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest whole-body cooling
Number of subjects: 10
Study 18657676 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1572
Study 18657676 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 15811487 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient clinical trials handbook (experimental group)
Number of subjects: 90
Study 15811487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no handbook)
Number of subjects: 90
Study 12618501 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (30 mg/m²)
Number of subjects: 698
Study 12618501 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1200 mg/m²)
Number of subjects: 698
Study 12618501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (25 mg/m²) plus Gemcitabine (1000 mg/m²)
Number of subjects: 698
Study 12618501 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life across all treatment arms
Number of subjects: 698
Study 10588229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfen
Number of subjects: 941
Study 10588229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfen SR
Number of subjects: 941
Study 10588229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 10588229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Dexfen groups
Number of subjects: 941
Study 8934869 — intervention group
Group type: EXPERIMENTAL
Intervention: High Reprimand Consistency with Attend response
Number of subjects: 18
Study 8934869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Reprimand Consistency with Attend response
Number of subjects: 18
Study 8934869 — intervention group
Group type: EXPERIMENTAL
Intervention: High Reprimand Consistency with Ignore response
Number of subjects: 18
Study 8934869 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Reprimand Consistency with Ignore response
Number of subjects: 18
Study 8145392 — intervention group
Group type: EXPERIMENTAL
Intervention: Males spending 7 hours or more outside daily
Number of subjects: 424
Study 8145392 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with 4 or fewer remaining teeth
Number of subjects: 424
Study 3021500 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg q.i.d.)
Number of subjects: 0
Study 3021500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29206774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 30
Study 29206774 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 30
Study 29206774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29206774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus-dominant vaginal microbiota
Number of subjects: 30
Study 29206774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal glycogen, serum estradiol, and estrone
Number of subjects: 30
Study 27756419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic esophagogastric anastomosis (IEA) after MIE
Number of subjects: 200
Study 27756419 — intervention group
Group type: COMPARATOR
Intervention: Cervical esophagogastric anastomosis (CEA) after MIE
Number of subjects: 200
Study 23427974 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine ATLS course
Number of subjects: 2
Study 23427974 — intervention group
Group type: COMPARATOR
Intervention: Standard on-site ATLS course
Number of subjects: 2
Study 21342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide and eugenol cement (ZOE)
Number of subjects: 31
Study 21342437 — intervention group
Group type: EXPERIMENTAL
Intervention: Calen(®) paste thickened with zinc oxide (Calen(®) /ZO)
Number of subjects: 31
Study 19723986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-substituting rotating-platform design
Number of subjects: 273
Study 19723986 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing design with an all-polyethylene tibial component
Number of subjects: 273
Study 17802785 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-MB 91
Number of subjects: 713
Study 17802785 — intervention group
Group type: COMPARATOR
Intervention: ALL-BFM 90m
Number of subjects: 713
Study 14631124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with azathioprine (AZA) and interferon beta(1a)
Number of subjects: 23
Study 11396998 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (recombinant human form of granulocyte colony‐stimulating factor)
Number of subjects: 30
Study 11396998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9407252 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake (CHO) of 10 g.kg‐1 bm during the 22‐hr recovery
Number of subjects: 6
Study 9407252 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet (CON) with extra protein and fat
Number of subjects: 6
Study 8498900 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rh‐EPO) therapy
Number of subjects: 362
Study 8498900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rh‐EPO therapy in the first year)
Number of subjects: 362
Study 3079056 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 112
Study 3079056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphoblast globulin (ALG) therapy
Number of subjects: 112
Study 3079056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 28752418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (120 mg docosahexaenoic acid and 180 mg eicosapentaenoic acid) daily
Number of subjects: 150
Study 28752418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27626142 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in emmetropic eyes (EE)
Number of subjects: 30
Study 27626142 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in highly myopic eyes (ME)
Number of subjects: 30
Study 27626142 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Drinking Test (WDT) in both groups (EE and ME)
Number of subjects: 30
Study 27626142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) during WDT in highly myopic eyes (ME)
Number of subjects: 30
Study 24942756 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated, granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)‐secreting, allogeneic PDAC vaccine (GVAX)
Number of subjects: 39
Study 24942756 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX in combination with low‐dose cyclophosphamide
Number of subjects: 39
Study 24942756 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX
Number of subjects: 39
Study 22526159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treosulfan (7,000 mg/m2 on day 1 of a 28-day cycle)
Number of subjects: 51
Study 22526159 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treosulfan (600 mg/m2 on days 1-28 of a 56-day cycle)
Number of subjects: 51
Study 20732718 — intervention group
Group type: EXPERIMENTAL
Intervention: MB11 BERAphone
Number of subjects: 54
Study 20732718 — intervention group
Group type: COMPARATOR
Intervention: ALGOportable
Number of subjects: 54
Study 18374336 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 125
Study 18374336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 125
Study 18374336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and simvastatin
Number of subjects: 125
Study 15991880 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg following a standard high‐fat content meal
Number of subjects: 12
Study 15991880 — intervention group
Group type: COMPARATOR
Intervention: Eslicarbazepine acetate 800 mg following 10 hours of fasting
Number of subjects: 12
Study 12495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfated polysaccharides from red microalgae (topical application)
Number of subjects: 0
Study 12495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfated polysaccharides from red microalgae (in vitro)
Number of subjects: 0
Study 10384681 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 administered via in-person or telephone interviews
Number of subjects: 31
Study 10384681 — intervention group
Group type: COMPARATOR
Intervention: Self-administered SF-36
Number of subjects: 31
Study 8679062 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidementia drug tacrine
Number of subjects: 0
Study 8679062 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-COG total score
Number of subjects: 0
Study 8679062 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor scores
Number of subjects: 0
Study 8679062 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures ANOVA
Number of subjects: 0
Study 1678518 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor intervention (single consultation and pamphlet)
Number of subjects: 338
Study 1678518 — intervention group
Group type: EXPERIMENTAL
Intervention: Major intervention (extensive interview and follow-up consultations)
Number of subjects: 338
Study 1678518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 338
Study 7070885 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg albuterol syrup (2 mg/5 ml) four times a day
Number of subjects: 20
Study 7070885 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg albuterol syrup
Number of subjects: 20
Study 7070885 — intervention group
Group type: COMPARATOR
Intervention: 4 mg albuterol tablets
Number of subjects: 20
Study 7070885 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg albuterol
Number of subjects: 20
Study 31750709 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments based on core representations; prompting to consider the entire distribution of others' preferences (Study 10)
Number of subjects: 17594
Study 31750709 — intervention group
Group type: EXPERIMENTAL
Intervention: Core representation uniformly positive (Studies 8A-8B)
Number of subjects: 17594
Study 31750709 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgments of others' preferences (Studies 9A-9B)
Number of subjects: 17594
Study 31750709 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of preferences (Study 7)
Number of subjects: 17594
Study 31750709 — intervention group
Group type: EXPERIMENTAL
Intervention: General experience representation (Studies 1-5, Study 6)
Number of subjects: 17594
Study 30831103 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 800 mcg every 3 hours for three doses
Number of subjects: 401
Study 30831103 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol 800 mcg every 3 hours for three doses
Number of subjects: 401
Study 30831103 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol with additional misoprostol at follow-up
Number of subjects: 401
Study 30831103 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol with additional misoprostol at follow-up
Number of subjects: 401
Study 30831103 — intervention group
Group type: COMPARATOR
Intervention: Sublingual misoprostol
Number of subjects: 401
Study 28724016 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) plus regular care
Number of subjects: 0
Study 28724016 — intervention group
Group type: COMPARATOR
Intervention: Regular programs provided by the institution
Number of subjects: 0
Study 28724016 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analysis of all participants
Number of subjects: 0
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign tumors (n = 13)
Number of subjects: 17
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant tumors (n = 4)
Number of subjects: 17
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign tumors post-surgery
Number of subjects: 17
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant tumors post-surgery
Number of subjects: 17
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall neurophysiological assessments
Number of subjects: 17
Study 24740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle EMG, ENG and BR examinations
Number of subjects: 17
Study 25277158 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session mother-infant intervention (HUGS: Happiness Understanding Giving and Sharing)
Number of subjects: 100
Study 25277158 — intervention group
Group type: COMPARATOR
Intervention: 4-session attention placebo playgroup (Playtime)
Number of subjects: 100
Study 22035285 — intervention group
Group type: EXPERIMENTAL
Intervention: SA and CDP + BPO
Number of subjects: 49
Study 22035285 — intervention group
Group type: COMPARATOR
Intervention: CDP + BPO
Number of subjects: 49
Study 19358928 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional food containing DHA
Number of subjects: 59
Study 19358928 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma PLs
Number of subjects: 59
Study 19358928 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal RBC PLs
Number of subjects: 59
Study 17237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Formats with a number (e.g., pie charts, vertical bars, horizontal bars, digits, systematic ovals, random ovals)
Number of subjects: 216
Study 17237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Formats with only a scale (e.g., pie charts, random ovals)
Number of subjects: 216
Study 17237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical bars with scales
Number of subjects: 216
Study 17237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreground and background color variations (black and white vs. blue and yellow; white vs. blue)
Number of subjects: 216
Study 17237451 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic ovals with a scale
Number of subjects: 216
Study 15281471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI, 400 microg every evening (1 puff daily)
Number of subjects: 167
Study 15281471 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate MDI, two 125-microg puffs twice daily
Number of subjects: 167
Study 15281471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI
Number of subjects: 167
Study 15281471 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate MDI
Number of subjects: 167
Study 12045412 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medications for treatment of status asthmaticus; specific drugs, doses, and duration not available.
Number of subjects: 0
Study 12045412 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of cost-adding treatments without improved quality of care; specific interventions not available.
Number of subjects: 0
Study 9471047 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatic artery ligation (Group I)
Number of subjects: 75
Study 9471047 — intervention group
Group type: COMPARATOR
Intervention: Spermatic artery preservation (Group II)
Number of subjects: 75
Study 9346617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (DIL group)
Number of subjects: 32
Study 9346617 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (NIF group)
Number of subjects: 32
Study 2172395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone (168 micrograms twice a day) and oral prednisone (30 mg twice daily)
Number of subjects: 45
Study 2172395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 101432 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0
Study 31253226 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin combined with pantoprazole
Number of subjects: 82
Study 31253226 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole
Number of subjects: 82
Study 28541633 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval (TI) ≤4 weeks
Number of subjects: 110
Study 28541633 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval (TI) >4 weeks
Number of subjects: 110
Study 28541633 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval (TI) ≤6 weeks
Number of subjects: 110
Study 28541633 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval (TI) >6 weeks
Number of subjects: 110
Study 28541633 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval (TI) >4 weeks in squamous cell carcinoma
Number of subjects: 110
Study 28541633 — intervention group
Group type: COMPARATOR
Intervention: Deep stromal invasion
Number of subjects: 110
Study 28541633 — intervention group
Group type: COMPARATOR
Intervention: Parametrial involvement (PI)
Number of subjects: 110
Study 28541633 — intervention group
Group type: COMPARATOR
Intervention: Tumor size
Number of subjects: 110
Study 25728612 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 150 µg/day
Number of subjects: 591
Study 25728612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591
Study 24471250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (loading dose of 60 mg followed by maintenance dose of 10 mg once daily)
Number of subjects: 210
Study 24471250 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (loading dose of 300 mg followed by maintenance dose of 75 mg once daily)
Number of subjects: 210
Study 21212103 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide LAR (60 mg/28 days)
Number of subjects: 26
Study 21212103 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency octreotide LAR (30 mg/21 days)
Number of subjects: 26
Study 21212103 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose octreotide LAR
Number of subjects: 26
Study 18217176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Organ Prolapse Quantification Index (POP-Q-I)
Number of subjects: 50
Study 17302367 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380 30 mg once per day
Number of subjects: 29
Study 17302367 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380 60 mg once per day
Number of subjects: 29